• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    2/29/24 8:07:01 AM ET
    $AMPE
    $BFLY
    $CLPT
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Electronics
    Health Care
    Get the next $AMPE alert in real time by email

    Gainers

    • Enveric Biosciences (NASDAQ:ENVB) stock rose 162.3% to $2.18 during Thursday's pre-market session. The company's market cap stands at $5.9 million.
    • Societal CDMO (NASDAQ:SCTL) shares moved upwards by 134.78% to $1.08. The company's market cap stands at $113.1 million.
    • NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 45.11% to $7.43. The company's market cap stands at $36.4 million.
    • OneMedNet (NASDAQ:ONMD) stock moved upwards by 28.97% to $0.89. The market value of their outstanding shares is at $28.7 million.
    • Establishment Labs Hldgs (NASDAQ:ESTA) stock increased by 21.91% to $46.89. The market value of their outstanding shares is at $1.2 billion. As per the press release, Q4 earnings came out yesterday.
    • Avidity Biosciences (NASDAQ:RNA) shares moved upwards by 20.64% to $18.41. The market value of their outstanding shares is at $1.4 billion. As per the press release, Q4 earnings came out yesterday.

    Losers

    • Ironwood Pharmaceuticals (NASDAQ:IRWD) shares decreased by 27.7% to $10.94 during Thursday's pre-market session. The company's market cap stands at $1.7 billion.
    • Milestone Pharmaceuticals (NASDAQ:MIST) stock fell 20.19% to $1.7. The market value of their outstanding shares is at $56.9 million.
    • Butterfly Network (NYSE:BFLY) stock fell 14.19% to $1.27. The company's market cap stands at $263.0 million. The company's, Q4 earnings came out yesterday.
    • Schrodinger (NASDAQ:SDGR) stock fell 13.3% to $27.2. The market value of their outstanding shares is at $1.9 billion. The company's, Q4 earnings came out yesterday.
    • ClearPoint Neuro (NASDAQ:CLPT) shares declined by 13.22% to $6.7. The company's market cap stands at $164.9 million.
    • Ampio Pharmaceuticals (AMEX:AMPE) stock fell 13.05% to $2.0. The market value of their outstanding shares is at $2.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMPE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMPE
    $BFLY
    $CLPT
    $ENVB

    CompanyDatePrice TargetRatingAnalyst
    Ironwood Pharmaceuticals Inc.
    $IRWD
    1/5/2026$8.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Milestone Pharmaceuticals Inc.
    $MIST
    12/15/2025$8.00Hold → Buy
    TD Cowen
    Schrodinger Inc.
    $SDGR
    12/15/2025$24.00Neutral → Buy
    BofA Securities
    Schrodinger Inc.
    $SDGR
    9/30/2025$19.00Neutral
    Goldman
    Atrium Therapeutics Inc.
    $RNA
    9/17/2025$62.00Buy
    Roth Capital
    Milestone Pharmaceuticals Inc.
    $MIST
    9/11/2025$4.00Overweight
    Wells Fargo
    Establishment Labs Holdings Inc.
    $ESTA
    8/20/2025$60.00Buy
    Canaccord Genuity
    Schrodinger Inc.
    $SDGR
    8/15/2025$20.00Buy → Neutral
    Citigroup
    More analyst ratings

    $AMPE
    $BFLY
    $CLPT
    $ENVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ironwood Pharma upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Ironwood Pharma from Mkt Perform to Mkt Outperform and set a new price target of $8.00

    1/5/26 8:35:09 AM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milestone Pharmaceuticals upgraded by TD Cowen with a new price target

    TD Cowen upgraded Milestone Pharmaceuticals from Hold to Buy and set a new price target of $8.00

    12/15/25 10:09:22 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrodinger upgraded by BofA Securities with a new price target

    BofA Securities upgraded Schrodinger from Neutral to Buy and set a new price target of $24.00

    12/15/25 9:09:21 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPE
    $BFLY
    $CLPT
    $ENVB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $AMPE
    $BFLY
    $CLPT
    $ENVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Phanstiel S. Louise bought $571,160 worth of shares (185,261 units at $3.08) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/17/25 4:10:13 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Director Robbins Larry bought $64,471 worth of shares (21,370 units at $3.02) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/15/25 6:20:36 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Director Robbins Larry bought $4,652,773 worth of shares (1,558,541 units at $2.99) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/5/25 5:40:49 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $AMPE
    $BFLY
    $CLPT
    $ENVB
    SEC Filings

    View All

    SEC Form 144 filed by Butterfly Network Inc.

    144 - Butterfly Network, Inc. (0001804176) (Subject)

    3/5/26 4:42:18 PM ET
    $BFLY
    Medical Electronics
    Health Care

    SEC Form 144 filed by Schrodinger Inc.

    144 - Schrodinger, Inc. (0001490978) (Subject)

    3/5/26 3:05:19 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Butterfly Network Inc.

    144 - Butterfly Network, Inc. (0001804176) (Subject)

    3/3/26 4:54:46 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $AMPE
    $BFLY
    $CLPT
    $ENVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, March 11th at 4:00 p.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ:IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a ne

    3/4/26 4:05:00 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes

    Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 3, 2026 /CNW/ -- USANewsGroup.com News Commentary -- AI is making its way through the halls of our entire medical system, and the implementation is accelerating at a great pace. The AI medical imaging market is projected to hit nearly $20 billion by 2033, growing at a 34.7% CAGR[1]. Echocardiography alone is forecast to grow to $2.64 billion by 2030 as hospitals demand cardiac platforms that prove economic value alongside clinical accuracy[2]. Companies like VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Butterfly Network (NYSE:BFLY), Tempus AI (NASDAQ:TEM), RadNet (NASDAQ:RDNT), and GE HealthCare (NASDAQ:GEHC) are conv

    3/3/26 12:19:00 PM ET
    $BFLY
    $GEHC
    $RDNT
    Medical Electronics
    Health Care
    Medical Specialities
    Computer Software: Programming Data Processing

    Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies

    Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform Lead candidates ATR 1072 and ATR 1086 expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy, respectivelySAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) launched today as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people living with rare, life-threatening genetic cardiomyopathies. Atrium Therapeutics was established in connection with Avidity Biosciences, Inc.'s acquisition by Novartis AG. The company is led by Kathl

    2/27/26 9:19:00 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPE
    $BFLY
    $CLPT
    $ENVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CAO Herman Jenny sold $17,764 worth of shares (1,383 units at $12.84), decreasing direct ownership by 4% to 34,804 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    3/6/26 5:29:46 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & CFO Jain Rachit sold $21,033 worth of shares (1,631 units at $12.90), decreasing direct ownership by 3% to 52,596 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    3/6/26 5:29:05 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CLO & CPO Tran Yvonne sold $14,107 worth of shares (1,094 units at $12.89), decreasing direct ownership by 2% to 52,683 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    3/6/26 5:28:37 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPE
    $BFLY
    $CLPT
    $ENVB
    Leadership Updates

    Live Leadership Updates

    View All

    Establishment Labs Announces Leadership Transition to Support Next Phase of Growth

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced a strategic leadership transition of Raj Denhoy, current Chief Financial Officer to Senior Vice President, Global Strategy, and the appointment of Cassandra "Sandra" Harris to Senior Vice President and Chief Financial Officer, effective March 9, 2026. "Over the past few years, we have been focused on driving efficient execution and scalability. With the company well positioned for its next chapter of growth, we are creating additional leadership capacity to maintain operational momentum

    2/24/26 8:00:00 AM ET
    $ESTA
    $GCO
    Industrial Specialties
    Health Care
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

    MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval's appointment comes as Milestone launches CARDAMYST™ (etripamil) nasal spray, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025. He will serve as a member of Milestone's executive leadership team and will provide business-focused legal counsel across all

    2/10/26 8:00:00 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman

    ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr. Johnson will work alongside CEO, Doron Besser, and the existing leadership team. David Johnson, newly appointed Chairman of ENvue, stated, "We believe ENvue is at the forefront of advanced feeding-tube placement technology, which has been validated in the market and extensively used in the clinic across 38 hospitals in the US. In my opinion, the Company's unique feeding tube placement system that utilizes advanced methods of navigation, integrated sensors and body mapping h

    12/15/25 9:00:00 AM ET
    $ENVB
    $FEED
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    $AMPE
    $BFLY
    $CLPT
    $ENVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Avidity Biosciences Inc.

    SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)

    11/14/24 5:46:11 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Enveric Biosciences Inc.

    SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)

    11/14/24 4:03:47 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by NeuroBo Pharmaceuticals Inc.

    SC 13G - NeuroBo Pharmaceuticals, Inc. (0001638287) (Subject)

    11/14/24 3:34:00 PM ET
    $NRBO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPE
    $BFLY
    $CLPT
    $ENVB
    Financials

    Live finance-specific insights

    View All

    Butterfly Network Reports Fourth Quarter 2025 Financial Results

    Delivered Record Annual and Quarterly Revenue Reported quarterly record Revenue of $31.5 million in Q4, representing 41% YoY growth Generated positive net cash flow of $6.3 million in Q4 and lowest annual cash usage in company history Midjourney partnership contributed $6.8 million of revenue in Q4, advancing Butterfly Embedded™ platform strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with semiconductor chip-based ultrasound devices, software and AI, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. Joseph DeVivo, Butterfly's Presiden

    2/26/26 6:30:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results

    2025 Total Revenue of $256 Million 2025 Software Revenue of $200 Million; 2025 Software ACV of $198 Million Strong Balance Sheet Supports Path to Positive Adjusted EBITDA by Year-End 2028 Accelerating Transition to Ratable, Hosted Software Revenue Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the fourth quarter and full-year ended December 31, 2025, and provided its 2026 outlook and 2028 financial objectives. "Schrödinger's performance in 2025, marked by 23% total revenue growth and 11% software revenue growth, is a testament to the resilience of our business and the unique value we provide," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "

    2/25/26 4:05:00 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook

    – LINZESS® (linaclotide) EUTRx demand growth of 11% for full year 2025 year-over-year – – 2025 Ironwood revenue of $296 million, GAAP net income of $24 million and adjusted EBITDA of $138 million – – Continue to expect full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million – – Key elements of confirmatory Phase 3 clinical trial design of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) have been finalized with site initiations expected to begin in the second quarter of 2026 – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and comm

    2/25/26 7:05:00 AM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care